AQST News & Events

Aquestive Therapeutics announced that multiple poster presentations highlighting results from the investigational use of its product candidate Anaphylm sublingual film for the treatment of severe allergic reactions, including anaphylaxis, will be featured at the 2026 American Academy of Allergy, Asthma and Immunology, AAAAI, Annual Meeting. The meeting will take place February 27-March 2, 2026, in Philadelphia, PA. "We are pleased to present additional clinical data at AAAAI highlighting Anaphylm's differentiated profile," said Daniel Barber, President and Chief Executive Officer of Aquestive. "These results build on our work to date, which is substantial and underscores Anaphylm's potential to deliver clinically meaningful outcomes while offering an easy-to-carry alternative to injectable epinephrine. Designed to address the practical and psychological barriers that have prevented consistent epinephrine carriage and use for decades, Anaphylm has the potential to transform anaphylaxis management. Allergy patients need continued innovation designed to overcome well-understood preparedness and treatment barriers."

Aquestive Therapeutics announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chief Medical Officer, strengthening its leadership team as the Company prepares to resubmit its Anaphylm New Drug Application, NDA, to the United Stated Food and Drug Administration, FDA, and advance its clinical pipeline. Greenhawt most recently served as Chief Medical Officer of the Asthma and Allergy Foundation of America